Syntrix

Illumina has asked a federal court to dismiss a six-month-old trademark infringement lawsuit against Illumavista Biosciences following an apparent out-of-court settlement.

While Syntrix Biosystems may have played a role in developing foundational microarray technology, the company does not intend to use a large, recently awarded royalty payment from Illumina to expand its presence in the array market.

This story was originally posted on March 15.

NEW YORK (GenomeWeb News) – A federal court jury has ordered Illumina to pay $96 million in damages to Syntrix Biosystems in a patent infringement case.

A jury is considering whether Illumina has infringed the intellectual property of Syntrix, a company with whom the San Diego vendor discussed a potential business relationship more than a decade ago.

Illumina denies that its arrays infringe Syntrix's IP and has asked the court to declare that the patent at the heart of the case is invalid and that the suit be dismissed with prejudice.

In the suit, Syntrix alleges that Illumina has based its array products on technology developed originally by Syntrix and provided confidentially to Illumina a decade ago while the two firms were discussing a possible business relationship.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.